Repurposing Imeglimin for Chemotherapy-Induced Cognitive Impairment: Targeting Mitochondrial Dysfunction and...

Area of Science:

• Neuroscience and Pharmacology
• Oncology and Cancer Therapeutics

Background:

• Chemotherapy-induced cognitive impairment (CICI), or chemo brain, significantly impacts memory, attention, and executive functions.
• Key CICI mechanisms include oxidative stress, mitochondrial dysfunction, neuroinflammation, insulin resistance, and reduced neurogenesis.

Purpose of the Study:

• To explore the potential of imeglimin, a novel antidiabetic medication, as a therapeutic agent for chemo brain.
• To critically assess imeglimin's mechanistic plausibility, pharmacological constraints, and validation gaps in mitigating CICI.

Main Methods:

• Review of existing literature on imeglimin's pharmacological actions and CICI's underlying pathophysiology.
• Hypothesis-driven translational framework to evaluate imeglimin's potential benefits against chemotherapy-induced cognitive deficits.

Main Results:

• Imeglimin demonstrates neuroprotective properties by enhancing mitochondrial function, reducing oxidative stress, and improving redox homeostasis.
• Imeglimin exhibits anti-inflammatory effects by suppressing NF-κB signaling and reducing pro-inflammatory cytokines, potentially mitigating neuroinflammation.
• Imeglimin improves insulin sensitivity and brain glucose metabolism, addressing the 'type 3 diabetes' concept of chemo brain and enhancing synaptic plasticity.

Conclusions:

• Imeglimin's multifaceted actions on mitochondria and inflammation suggest potential for alleviating chemo brain pathology.
• Further preclinical and clinical evaluations are essential to validate imeglimin's therapeutic efficacy in managing chemotherapy-induced cognitive impairment.